Skip to main content
رجوع
CRL logo

Charles River Laboratories International, Inc.

جودة البيانات: 100%
CRL
NYSE Healthcare Medical - Diagnostics & Research
KWD 158.00
▲ KWD 4.40 (2.86%)
القيمة السوقية: 7.78B
نطاق اليوم
KWD 154.49 KWD 159.35
نطاق 52 أسبوعًا
KWD 91.86 KWD 228.88
حجم التداول
602,544
متوسط 50 يوم / 200 يوم
KWD 186.54 / KWD 173.06
الإغلاق السابق
KWD 153.60

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -53.9 0.4
P/B 2.5 2.9
ROE % -4.4 3.7
Net Margin % -3.6 3.9
Rev Growth 5Y % 3.2 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

Hold
KWD 202.170 +28.0%
Low: KWD 175.000 High: KWD 260.000
مكرر الربحية المستقبلي
14.3
ربحية السهم المستقبلية
KWD 11.069
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
4 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 15.495
KWD 15.356 – KWD 15.630
4.6 B 1
FY2029 KWD 14.067
KWD 13.940 – KWD 14.189
4.6 B 1
FY2028 KWD 13.185
KWD 13.066 – KWD 13.299
4.3 B 1

النقاط الرئيسية

Revenue grew 3.20% annually over 5 years — modest growth
Earnings declined -1501.75% over the past year
Generating 518.49M in free cash flow
PEG of 0.05 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 4.05%
Capital efficient — spends only 5.46% of revenue on capex

النمو

Revenue Growth (5Y)
3.20%
Revenue (1Y)-0.85%
Earnings (1Y)-1501.75%
FCF Growth (3Y)19.13%

الجودة

Return on Equity
-4.36%
ROIC6.11%
Net Margin-3.59%
Op. Margin12.65%

الأمان

Debt / Equity
0.97
Current Ratio1.29
Interest Coverage4.74

التقييم

P/E Ratio
-53.89
P/B Ratio2.46
EV/EBITDA20.93
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -0.85% Revenue Growth (3Y) -1.39%
Earnings Growth (1Y) -1501.75% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3.20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.02B Net Income (TTM) -144.34M
ROE -4.36% ROA -2.02%
Gross Margin 30.52% Operating Margin 12.65%
Net Margin -3.59% Free Cash Flow (TTM) 518.49M
ROIC 6.11% FCF Growth (3Y) 19.13%
Safety
Debt / Equity 0.97 Current Ratio 1.29
Interest Coverage 4.74 Dividend Yield 0.00%
Valuation
P/E Ratio -53.89 P/B Ratio 2.46
P/S Ratio 1.94 PEG Ratio 0.05
EV/EBITDA 20.93 Dividend Yield 0.00%
Market Cap 7.78B Enterprise Value 10.63B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.02B 4.05B 4.13B 3.98B 3.54B
Net Income -144.34M 10.30M 474.62M 486.23M 390.98M
EPS (Diluted) -2.91 0.20 9.22 9.48 7.60
Gross Profit 1.23B 1.33B 1.50B 1.46B 1.33B
Operating Income 507.84M 227.35M 617.26M 650.98M 589.86M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.14B 7.53B 8.20B 7.60B 7.02B
Total Liabilities 3.92B 4.02B 4.54B 4.58B 4.43B
Shareholders' Equity 3.16B 3.46B 3.60B 2.98B 2.53B
Total Debt 3.07B 2.72B 3.07B 3.10B 3.21B
Cash & Equivalents 213.77M 194.61M 276.77M 233.91M 245.24M
Current Assets 1.45B 1.40B 1.61B 1.44B 1.27B
Current Liabilities 1.12B 994.10M 1.06B 1.09B 1.03B